文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

立体定向体部放疗作为寡转移性前列腺癌转移灶导向治疗:随机对照试验的系统综述与Meta分析

Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Radiat Oncol · 2024-12-17

该系统综述与Meta分析检索MEDLINE、Embase、CINAHL Complete和Cochrane Library(2023年10月28日),纳入7项II期随机对照试验共559例合格参与者,比较立体定向体部放疗作为转移灶导向治疗与不做转移灶导向治疗在颅外寡转移性前列腺癌中的疗效与安全性。Meta分析显示≥3级毒性无差异(合并风险比0.78,95%CI 0.37-1.65,P=0.52),4项试验报告无进展生存期显著延长(合并风险比0.31,95%CI 0.21-0.45,P<0.00001),总生存比较尚不成熟。

要点

  • 7项II期随机对照试验共559例合格参与者纳入分析,其中4项试验纳入多种原发癌类型。
  • 两项试验≥3级毒性Meta分析无差异:合并风险比0.78(95%CI 0.37-1.65,P=0.52)。
  • 4项试验报告无进展生存期显著延长:合并风险比0.31(95%CI 0.21-0.45,P<0.00001)。

核心结论

  • II期试验显示立体定向体部放疗在多种寡转移性前列腺癌状态下无进展生存期有前景的改善,且无超额毒性。
  • 总生存比较尚不成熟。
  • 未来确证性III期试验中,足够大的样本量、结局评估者设盲和/或提高对分配干预的依从性可提高证据质量。

研究设计与样本

  • 检索MEDLINE、Embase、CINAHL Complete和Cochrane Library,检索日期为2023年10月28日。
  • 纳入比较立体定向体部放疗作为转移灶导向治疗与不做转移灶导向治疗在颅外寡转移性前列腺癌中的随机对照试验,对随访时间、发表状态、语言或年份无限制。
  • 共识别1825份唯一研究报道,纳入7项II期随机对照试验共559例合格参与者,其中4项试验纳入多种原发癌类型。
  • 采用Cochrane偏倚风险评估工具第2版评估偏倚风险,采用推荐分级的评估、制定与评价(GRADE)评估证据质量。

主要发现

  • 除总生存和毒性外,各试验结局定义存在异质性。
  • 总生存方面仅1项研究报告了两组的事件。
  • 两项试验≥3级毒性的Meta分析显示无差异:合并风险比0.78(95%CI 0.37-1.65,P=0.52)。
  • 4项试验报告无进展生存期显著延长:合并风险比0.31(95%CI 0.21-0.45,P<0.00001)。
  • 偏倚风险为有一定担忧或高,证据质量为低或中等。

关键数值与推荐

  • 关键结局为总生存和≥3级毒性;其他重要结局为无进展生存期、局部控制、5级毒性、健康相关生活质量和无全身治疗生存期。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 各试验结局定义存在异质性(总生存和毒性除外)。
  • 总生存方面仅1项研究报告了两组的事件,总生存比较尚不成熟。
  • 偏倚风险为有一定担忧或高。
  • 证据质量为低或中等。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of stereotactic body radiotherapy (SBRT) to definitively treat oligometastases in prostate cancer has drawn large clinical and research interests within radiation oncology. However, the evidence is considered in its early stages and there is currently no systematic review of randomized controlled trials (RCTs) in this field. We aimed to evaluate the efficacy and safety of SBRT as metastasis-directed therapy (MDT) in oligometastatic prostate cancer (OMPC) compared to no MDT reported in RCTs. METHODS: MEDLINE, Embase, CINAHL Complete, and Cochrane Library were searched on October 28, 2023. Eligible studies were RCTs comparing SBRT as MDT with no MDT in extracranial OMPC, without restrictions on follow-up time, publication status, language, or year. Participant subsets fulfilling the eligibility criteria were included. Critical outcomes were overall survival and grade ≥ 3 toxicity, and additional important outcomes were progression-free survival (PFS), local control, grade 5 toxicity, health-related quality of life, and systemic therapy-free survival. Meta-analyses were planned. Risk of bias was assessed using the Cochrane risk-of-bias tool version 2, and the quality of evidence using the Grading of Recommendations Assessment, Development, and Evaluation. RESULTS: In total, 1825 unique study reports were identified and seven phase II RCTs with 559 eligible participants were included. Four trials included multiple types of primary cancer. Outcome definitions were heterogeneous except for overall survival and toxicity. For overall survival, only one study reported events in both arms. Meta-analysis of the grade ≥ 3 toxicity results from two trials showed no difference (pooled risk ratio 0.78, 95% confidence interval 0.37-1.65, p = 0.52). Four trials reported significantly longer PFS, with a pooled hazard ratio of 0.31 (95% confidence interval 0.21-0.45, p < 0.00001). Risk of bias was of some concerns or high. Quality of evidence was low or moderate. CONCLUSIONS: Phase II trials have shown promising improvements in PFS for several OMPC states without excess toxicity. Overall survival comparisons are immature. In future confirmatory phase III trials, adequately large sample sizes, blinding of outcome assessors, and/or increased adherence to assigned intervention could improve the quality of evidence. PROSPERO registration number: CRD42021230131.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Persson AE, Hallqvist A, Bjørn Larsen L, et al. Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials. Radiat Oncol. 2024. PMID: 39690404. doi:10.1186/s13014-024-02559-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。